Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 13/20 | 0.32 |
| ▸ | ATM | Q13315 | 4/20 | 0.32 |
| ▸ | PRKDC | P78527 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10309169 | 0.90 | PDPK1 (0.35) | PDPK1ATRATMPRKDC | |
| SCHEMBL10277425 | 0.88 | PDPK1 (0.33) | PDPK1ATRATMPRKDC | |
| SCHEMBL10277427 | 0.86 | PDPK1 (0.33) | PDPK1ATRATMPRKDC | |
| SCHEMBL2634674 | 0.85 | ATR (0.32) | PDPK1ATRATMPRKDC | |
| SCHEMBL10309170 | 0.84 | PDPK1 (0.36) | PDPK1ATRPRKDC | |
| SCHEMBL12186524 | 0.78 | ATR (0.39) | PDPK1ATRATMPRKDC | |
| SCHEMBL10141979 | 0.77 | ATR (0.41) | ATRATMPRKDC | |
| SCHEMBL10277784 | 0.76 | ATR (0.37) | ATRATMPRKDC | |
| SCHEMBL667542 | 0.76 | ATR (0.41) | ATRATMPRKDC | |
| SCHEMBL2634375 | 0.75 | ATR (0.36) | ATRATMPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969356-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-03 | — | — | US | disclosed |
| EP-2568984-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20120178756-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011143399-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178756-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | PDPK1 44/4885ATR 1/4885ATM 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.